Related Experiment Video
Updated: Jan 14, 2026
08:02
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
18.9K
Notoginsenoside R1 Improved Hypoxic Pulmonary Hypertension by Inhibiting Glycolysis-Mediated Pulmonary Arterial
Xiaowei Gong1, Yanling Sheng2, Gaijun Zhang3
1Department of Respiratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Canadian Respiratory Journal
|October 22, 2025
Summary
Notoginsenoside R1 (NGR1) effectively treats hypoxic pulmonary hypertension (HPH) in rats by inhibiting glycolysis and improving vascular remodeling. This study reveals NGR1
Area of Science:
- Cardiovascular Research
- Pulmonary Medicine
- Pharmacology
Background:
- Hypoxic pulmonary hypertension (HPH) presents a significant unmet therapeutic need.
- Current treatments for HPH are limited in efficacy.
- Understanding the molecular mechanisms underlying HPH is crucial for developing novel interventions.
Purpose of the Study:
- To investigate the therapeutic potential of Notoginsenoside R1 (NGR1) in a rat model of HPH.
- To elucidate the molecular mechanisms by which NGR1 exerts its effects on HPH.
- To assess the impact of NGR1 on hemodynamic parameters and pulmonary vascular remodeling.
Main Methods:
- Established a rat model of HPH induced by hypoxic conditions.
- Administered NGR1 to HPH rats and assessed therapeutic outcomes.
- Utilized hemodynamic measurements and pulmonary artery vascular remodeling assessments.
- Performed transcriptomic analysis to identify gene expression alterations.
- Conducted untargeted metabolomics to analyze metabolic profile changes.
Main Results:
- NGR1 treatment significantly improved hemodynamic parameters and reduced pulmonary artery vascular remodeling in HPH rats.
- Transcriptomic analysis highlighted altered expression of genes, including Pck1.
- NGR1 intervention normalized the expression of vascular remodeling-related proteins and reversed hypoxia-induced glycolysis-related gene expression.
- Metabolomic analysis showed reduced levels of glycolysis-related metabolites, including lactate, in NGR1-treated rats.
- NGR1 decreased the protein expression of PFKL, HK2, and LDHA.
Conclusions:
- Notoginsenoside R1 (NGR1) demonstrates significant efficacy in alleviating pathological features of HPH in a rat model.
- NGR1 inhibits hypoxia-induced glycolysis-mediated pulmonary artery remodeling.
- NGR1 mitigates vascular endothelial damage and suppresses the proliferation of vascular smooth muscle cells and fibroblasts in HPH.
- NGR1 represents a promising therapeutic candidate for treating hypoxic pulmonary hypertension.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
01:24Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
584
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
584
01:23Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
554
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
554